Oseltamivir

Treatment of influenza Adults and adolescents (13 years and older): 75 mg twice daily for 5 days Pediatric patients 1 to 12 years of age: Based on weight twice daily for 5 days Pediatric patients 2 weeks to less than 1 year of age: 3mg/kg twice daily for 5 days Renally impaired adult patients (creatinine clearance >30 to 60 mL/min): Reduce to 30 mg twice daily for 5 days Renally impaired adult patients (creatinine clearance >10 to 30 mL/min): Reduce to 30 mg once daily for 5 days ESRD patients on hemodialysis: Reduce to 30 mg immediately and then 30 mg after every hemodialysis cycle. Treatment duration not to exceed 5 days ESRD patients on CAPD: Reduce to a single 30 mg dose immediately Prophylaxis of influenza Adults and adolescents (13 years and older): 75 mg once daily

for at least 10 days Community outbreak: 75 mg once daily

for up to 6 weeks Pediatric patients 1 to 12 years of age: Based on weight once daily for 10 days Community outbreak: Based on weight once daily for up to 6 weeks Renally impaired adult patients (creatinine clearance >30 to 60 mL/min): Reduce to 30 mg once daily Renally impaired adult patients (creatinine clearance >10 to 30 mL/min): Reduce to 30 mg once every other day ESRD patients on hemodialysis: Reduce to 30 mg immediately and then 30 mg after alternate hemodialysis cycles

for the recommended duration of prophylaxis ESRD patients on CAPD: Reduce to 30 mg immediately and then 30 mg once weekly for the recommended duration of prophylaxis 2.Overview Administer oseltamivir phosphate for oral suspension for the treatment of influenza in patients 2 weeks of age or older [see] or for prophylaxis of influenza in patients 1 year and older [see] using: Oseltamivir phosphate for oral suspension (supplied as a powder). This is the preferred formulation (6 mg per mL) for patients who cannot swallow capsules. Prior to use, the supplied oseltamivir phosphate for oral suspension powder must be constituted with water by the pharmacist to produce the oral suspension [see].

for oral suspension (supplied as powder): a) Tap the closed bottle containing the supplied oseltamivir phosphate for oral suspension white to light yellow powder several times to loosen the powder. b) Tear off the foil seal after loosening the powder. c) Measure 55 mL of water in a graduated cylinder. d) Add the total amount of water for constitution to the bottle. e) Close bottle with child‐resistant cap tightly and shake the closed bottle well for 15 seconds. f) Label the bottle with instructions to “Shake Well Before Use”. g) The constituted oral suspension contains 360 mg of oseltamivir base per 60 mL of volume (6 mg per mL) and is white to light yellow, sour cherry-flavored).